Skip to main content
. 2021 Feb 2;21(4):245. doi: 10.3892/ol.2021.12506

Figure 2.

Figure 2.

EFS analysis of DLBCL patients with different subtypes following frontline R-CHOP treatment. (A) Comparison of EFS between high-FASN expression and low-FASN expression patients. (B) Comparison of EFS between DEL patients with high-FASN expression and the other patients. EFS, event-free survival; DLBCL, diffuse large B-cell lymphoma; DEL, double-expressor lymphoma; FASN, fatty acid synthase.